Skip to content

What Kind Of Year Will 2013 Be For Aegerion Pharmaceuticals And Orphan Drug Juxtapid ?: SeekingAlpha.com’s Perspective

January 11, 2013

       Orphan drug company Aegerion Pharmaceuticals is evaluated and reviewed in a SeekingAlpha.com article titled, “Aegerion: 2012 Was a Great Year But 2013 Could Be Better”. The pharmaceutical company had its orphan drug Juxtapid (Lomitapide) FDA approved, by a vote of 13 to 2, for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) on December 21, 2012.

According to a January 10, 2013 article from BioCentury.com titled, “Aegerion planning follow-on”, the following is the pricing information for Juxtapid :

–  US annual gross price/patient is $235,000 for 5 & 10 mg doses

–  US annual gross price/patient is $295,000 for 20, 40, & 60 mg doses

–  Per Juxtapid’s label, recommended initial dose is once-daily 5 mg, which can be titrated to 10, 20, 40, or 60 mg

–  FY13 expected global net revenues of approximately $15 – $25 million

–  250 – 300 patients on treatment by end of 2013.

 

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: